Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Document › Details

Neuway Pharma GmbH. (2/15). "Press Release: Neuway Pharma GmbH Signs License Agreement with University Zürich". Bonn & Zürich.

Organisations Organisation Neuway Pharma GmbH
  Organisation 2 University of Zurich (UZH)
Products Product drug delivery technology (drug formulation technology)
  Product 2 vaccine
Persons Person Manninga, Heiko (Neuway Pharma GmbH 201504 Managing Director)
  Person 2 Martin, Roland (Univ Zürich 201104– Professor + Head Dept Neuroimmunology at Univ Hospital Zürich before inims Hamburg)
     


University Zurich and NEUWAY Pharma GmbH, a German biotech start-up company, today announced that they have entered into a license agreement. Under the terms of this agreement NEUWAY will develop its technology to treat a rare but frequently fatal neurological disease called progessive multifocal leucoencephalopathy (PML).

Researchers at University Zurich found that NEUWAY’s engineered protein capsules (EPCs) may be used in the treatment of PML. EPCs have already been applied by clinical researchers at the university hospital of Zurich and found to enhance the immune response against the disease causing agent.

„With NEUWAY’s EPCs we have a promising tool for the therapy of PML“, says Dr. Roland Martin, clinical researcher at university Zurich, „however further clinical studies will be needed to determine safety and efficacy of this treatment option“.

For NEUWAY, the license agreement opens an additional business field: „Our primary goal is the use of EPCs as drug delivery system. In preclinical studies we found that EPCs show a low or even no immunogenicity. The immune response however could be enhanced by modulators to use empty EPCs as vaccine also”, says Heiko Manninga, Managing Director at NEUWAY.


About NEUWAY Pharma

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.


About Zürich University

The University of Zurich (UZH) is a member of the League of European Research Universities and numbers among Europe’s most prestigious research institutions. UZH’s international standing is reflected in the many renowned academic distinctions conferred upon its members, including twelve Nobel Prizes. As Switzerland’s largest university, UZH has a current enrollment of over 26,000 students and offers the most comprehensive academic program in the country. Over 5,000 excellent members of staff teach and perform research at one of the University’s 150 departments, including over 500 professors. UZH also looks back on a rich history, having been founded in 1833 as Europe’s first university to be established by a democratic political system.


Further information

NEUWAY Pharma GmbH:
Dr. Stephan Rapp, +49-(0)228-522198-0,
Press Contact:
Christine Kuhn, +49-(0)228-522198-0, kuhn@neuway.de
www.neuway.de

NEUWAY Pharma GmbH, Ludwig-Erhard-Allee 2, 53175 Bonn

   
Record changed: 2017-04-02

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Neuway Pharma GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81




» top